Effect of dalargin on repair capacity of gastroduodenal mucosa in patients with duodenal ulcer
Timoshin SS, Alekseenko SA, Shtuka AA · 1991 · Klin Med (Mosk). 1991;69(3):75-77. PMID 2067344
This source appears in the Thymalin–Dalargin evidence review. A single-agent experiment, comparative study or patent alternative is not automatically a combined-treatment trial.
Reported findings and study design
Narrative findings; numerical extraction incomplete
After 20 days, Dalargin was associated with a higher index of DNA-synthesizing epithelial nuclei in fundal and duodenal-bulb mucosa than conventional care. No numerical index was supplied.
Duodenal-ulcer patients treated with Dalargin or conventional spasmolytic/antacid care; group sizes unavailable in the checked abstract.
Dose, route and schedule
Twenty-day Dalargin course. Dose, route and administration frequency are unavailable in the checked abstract.
Protocol source ↗ · Original indexed abstract; historical research methods
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Mucosal DNA-synthesis marker | Significant increase in labelled epithelial nuclei described after Dalargin | Fundal and duodenal-bulb biopsies; exact indices, p-value and group sizes unavailable · 20 days |
| Clinical endpoint gap | No numerical ulcer-closure, relapse, symptom or safety comparison in the checked abstract |
Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.
Source for the extracted data ↗ · Checked 2026-11-08
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Historical active comparator; allocation, masking and other ulcer care require full text.
- A proliferation marker is not a demonstrated clinical healing or combination-treatment benefit.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original indexed abstract
Review depth: Indexed abstract and citation checked; full original outcome tables not recovered
Source access and review scope
Original PubMed / Europe PMC indexed abstract checked. Missing group sizes, doses, raw outcomes and uncertainty are not reconstructed.
Recorded source-check date: 2026-11-08. This date does not imply a completed systematic review.
Source type: Original journal publication
Citation and original source
Original source: Timoshin SS, Alekseenko SA, Shtuka AA. Effect of dalargin on repair capacity of gastroduodenal mucosa in patients with duodenal ulcer Klin Med (Mosk). 1991;69(3):75-77. PMID 2067344 1991.
Molekul research summary: https://molekul.io/research/dalargin-duodenal-dna-1991. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry